Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.47 |
| ▸ | BMP1 | P13497 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 5/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130820 | 0.95 | CAPN1 (0.47) | CAPN1BMP1CTSLADAM17CCR1 | |
| SCHEMBL4129767 | 0.94 | CAPN1 (0.47) | CAPN1BMP1CTSLADAM17CCR1 | |
| SCHEMBL5434781 | 0.92 | CAPN1 (0.44) | CAPN1BMP1CTSLADAM17CCR1 | |
| SCHEMBL5434829 | 0.91 | CAPN1 (0.44) | CAPN1BMP1CTSLADAM17CCR1 | |
| SCHEMBL5429199 | 0.88 | CAPN1 (0.47) | CAPN1BMP1CTSLADAM17CCR1 | |
| SCHEMBL4147709 | 0.86 | TRPV4 (0.44) | CAPN1CTSLCCR1TRPV4BCHE | |
| SCHEMBL4141710 | 0.86 | CAPN1 (0.49) | CAPN1BMP1CTSLADAM17CCR1 | |
| SCHEMBL5439592 | 0.86 | CAPN1 (0.45) | CAPN1CTSLCACNA1BBCHEREN | |
| SCHEMBL4140786 | 0.86 | TRPV4 (0.44) | CAPN1CTSLCCR1TRPV4BCHE | |
| SCHEMBL4142973 | 0.86 | CAPN1 (0.48) | CAPN1BMP1CTSLADAM17CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | claimed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | CAPN1 2884/4885BMP1 1833/4885CTSL 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.